Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to $47000.0.

  • NeuroPace's Asset Writedowns and Impairment fell 5607.48% to $47000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $244000.0, marking a year-over-year decrease of 757.58%. This contributed to the annual value of $300000.0 for FY2024, which is 5000.0% up from last year.
  • Per NeuroPace's latest filing, its Asset Writedowns and Impairment stood at $47000.0 for Q3 2025, which was down 5607.48% from $49000.0 recorded in Q2 2025.
  • NeuroPace's Asset Writedowns and Impairment's 5-year high stood at $138000.0 during Q2 2021, with a 5-year trough of $23000.0 in Q3 2021.
  • Its 5-year average for Asset Writedowns and Impairment is $59210.5, with a median of $47000.0 in 2024.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first tumbled by 9220.34% in 2021, then skyrocketed by 24166.67% in 2022.
  • NeuroPace's Asset Writedowns and Impairment (Quarter) stood at $57000.0 in 2021, then plummeted by 31.58% to $39000.0 in 2022, then soared by 74.36% to $68000.0 in 2023, then skyrocketed by 52.94% to $104000.0 in 2024, then tumbled by 54.81% to $47000.0 in 2025.
  • Its Asset Writedowns and Impairment was $47000.0 in Q3 2025, compared to $49000.0 in Q2 2025 and $44000.0 in Q1 2025.